TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23826970

Group type: EXPERIMENTAL
Intervention: Feedback Plus (ward meetings to discuss results and plan improvements)
Number of subjects: 4236

Group type: EXPERIMENTAL
Intervention: Basic Feedback (ward-specific printed patient survey results including patients' written comments sent to nurses by letter)
Number of subjects: 4236

Group type: COMPARATOR
Intervention: Control (no active feedback of survey results)
Number of subjects: 4236
Study: 20884847

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 5 schools)
Number of subjects: 498

Group type: COMPARATOR
Intervention: Control group (n = 5 schools)
Number of subjects: 498
Study: 18637080

Group type: EXPERIMENTAL
Intervention: IV butorphanol (1 mg)
Number of subjects: 46

Group type: COMPARATOR
Intervention: IV ketorolac (30 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 46
Study: 16905764

Group type: EXPERIMENTAL
Intervention: Clinical medication review by a pharmacist
Number of subjects: 661

Group type: COMPARATOR
Intervention: Usual general practitioner care
Number of subjects: 661
Study: 12969084

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg administered through a nasogastric tube
Number of subjects: 47

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg administered orally as an intact capsule
Number of subjects: 47
Study: 10871933

Group type: EXPERIMENTAL
Intervention: Dermabrasion
Number of subjects: 15

Group type: COMPARATOR
Intervention: Carbon dioxide laser resurfacing
Number of subjects: 15
Study: 8884304

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day for 7 days, Tinidazole 500 mg bid for 7 days, Clarithromycin 250 mg bid for 7 days (Group A)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Omeprazole 20 mg bid for 14 days, Amoxycillin 1000 mg bid for 14 days (Group B)
Number of subjects: 110
Study: 8257176

Group type: EXPERIMENTAL
Intervention: 'Few foods' elimination diet
Number of subjects: 78

Group type: COMPARATOR
Intervention: Provoking foods (in a placebo-controlled double-blind challenge)
Number of subjects: 78
Study: 4001769

Group type: EXPERIMENTAL
Intervention: Mebendazole 2 G per day for 14 days preceded by 300 mg of levamisole in 2 doses
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo vitamin tablets for 14 days
Number of subjects: 20
Study: 31440765

Group type: EXPERIMENTAL
Intervention: Individualized regular coaching and exercise
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Increased adherence to the intervention
Number of subjects: 362
Study: 29614378

Group type: EXPERIMENTAL
Intervention: Exposure-based internet-delivered cognitive behavior therapy (Internet-CBT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 101
Study: 27609678

Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 900

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 900
Study: 25473216

Group type: EXPERIMENTAL
Intervention: Silicone gel sheet
Number of subjects: 30

Group type: COMPARATOR
Intervention: Topical silicone gel
Number of subjects: 30
Study: 22297415

Group type: EXPERIMENTAL
Intervention: 10-week stretching program (right calf muscle stretched 4 times for 30 seconds, 3 days per week)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 25
Study: 20657532

Group type: EXPERIMENTAL
Intervention: Topical heparin spray (added to antiplatelet therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiplatelet therapy only
Number of subjects: 0
Study: 18830087

Group type: EXPERIMENTAL
Intervention: Adherence to Mediterranean-type diet (MeDiet)
Number of subjects: 3204
Study: 15967849

Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 37939

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 37939

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 37939

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 37939

Group type: COMPARATOR
Intervention: Control group (ACE I/D genotype)
Number of subjects: 37939
Study: 12581487

Group type: EXPERIMENTAL
Intervention: Ingested IFN-alpha in type 1 diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ingested IFN-alpha in rheumatoid arthritis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ingested IFN-alpha in multiple sclerosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ingested IFN-alpha (10,000 IU) in multiple sclerosis
Number of subjects: 0
Study: 11126694

Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estradiol patch
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate
Number of subjects: 0
Study: 9091475

Group type: EXPERIMENTAL
Intervention: Interferon gamma (IFN‐gamma) 100 micrograms subcutaneously for 5 consecutive days followed by 100 micrograms once weekly for 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7690364

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 300 mg im, each week for 6 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Nandrolone decanoate (ND) 300 mg im, each week for 6 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Nandrolone decanoate (ND)
Number of subjects: 11
Study: 3732048

Group type: COMPARATOR
Intervention: Adriamycin (A) and Cyclophosphamide (C)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Adriamycin (A) and Cis-platin
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Changing scheme (A/P-V/C-HD-MTX)
Number of subjects: 300
Study: 30324422

Group type: EXPERIMENTAL
Intervention: Phase III formulation with reduced SLS content, administered following a low-fat meal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phase I/II formulation, administered under the same conditions
Number of subjects: 0
Study: 26684776

Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral implantation
Number of subjects: 57

Group type: COMPARATOR
Intervention: Traditional sequential electrode implantation
Number of subjects: 57
Study: 24313246

Group type: EXPERIMENTAL
Intervention: Seeking Safety (SS; a cognitive‐behavioral intervention)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Women's Health Education (WHE; a control group intervention)
Number of subjects: 141
Study: 22237795

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural coping skills (CBCS); specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Counselling sessions; specific details not mentioned.
Number of subjects: 0
Study: 20529805

Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fludarabine and cyclophosphamide (FC)
Number of subjects: 0
Study: 18343253

Group type: EXPERIMENTAL
Intervention: Topical amethocaine gel 4%
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Nurses' assessment
Number of subjects: 110
Study: 15809408

Group type: EXPERIMENTAL
Intervention: Medications (paroxetine, up to 50 mg daily)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 12206277

Group type: EXPERIMENTAL
Intervention: 1st language (either Filipino or English)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2nd language (either Filipino or English)
Number of subjects: 0
Study: 10233784

Group type: EXPERIMENTAL
Intervention: Patent grafts (n = 409)
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Nontreated asymptomatic occlusions (n = 32)
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Nontreated symptomatic occlusions (n = 65)
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Subsequent revascularizations (n = 194)
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Successful revascularization
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Amputation (n = 36)
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Failed secondary revascularizations followed by secondary amputation (n = 38)
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: EuroQol score
Number of subjects: 746
Study: 8706447

Group type: EXPERIMENTAL
Intervention: MAK 195F (anti-TNF antibody) at 0.1 mg/kg
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: MAK 195F (anti-TNF antibody) at 0.3 mg/kg
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: MAK 195F (anti-TNF antibody) at 1.0 mg/kg
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 1758188

Group type: EXPERIMENTAL
Intervention: Diazepam 0.12 mg/kg
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Diazepam 0.2 mg/kg
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 31640924

Group type: EXPERIMENTAL
Intervention: PAC+F (physical activity counselling session plus provision of a Fitbit)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: PAC+F
Number of subjects: 52

Group type: COMPARATOR
Intervention: PAC
Number of subjects: 52
Study: 31150399

Group type: EXPERIMENTAL
Intervention: Virtual Reality Exposure (VRE) during three brief public speaking scenarios
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Second scenario of VRE
Number of subjects: 19
Study: 28168203

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 25835751

Group type: EXPERIMENTAL
Intervention: TX-001HR (solubilized 17β‐estradiol and natural progesterone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TX-001HR
Number of subjects: 0
Study: 24034909

Group type: EXPERIMENTAL
Intervention: NAVA (neurally adjusted ventilatory assist)
Number of subjects: 10

Group type: COMPARATOR
Intervention: SIMV (synchronized intermittent mandatory ventilation)
Number of subjects: 10
Study: 21357860

Group type: EXPERIMENTAL
Intervention: Subantimicrobial-dose-doxycycline (SDD)
Number of subjects: 128
Study: 19360538

Group type: EXPERIMENTAL
Intervention: Substance use onset (alcohol, cigarettes, dagga, inhalants)
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: Lifetime cigarette use
Number of subjects: 1118

Group type: EXPERIMENTAL
Intervention: Dagga (cannabis) and inhalant use
Number of subjects: 1118
Study: 18173524

Group type: EXPERIMENTAL
Intervention: NailQoL instrument
Number of subjects: 402
Study: 15086197

Group type: EXPERIMENTAL
Intervention: Abdominal drainage after liver resection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-drainage group
Number of subjects: 0
Study: 11469522

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 228

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study: 9883763

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 21
Study: 8032701

Group type: EXPERIMENTAL
Intervention: Different anti-emetics used in the trials
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimens
Number of subjects: 582
Study: 2915293

Group type: EXPERIMENTAL
Intervention: 100 mg/kg IVIG (Gamimune)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 20% dextrose (control)
Number of subjects: 16
Study: 977755

Group type: EXPERIMENTAL
Intervention: Initial highly structured leader role followed by a relatively unstructured leader role
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Structured throughout
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unstructured throughout
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unstructured to structured
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Structured to unstructured
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 0
Study: 30797491

Group type: EXPERIMENTAL
Intervention: EBUS‐GS guided bronchoscopy biopsy
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Combination of EBUS‐GS and virtual bronchoscopic navigation (VBN)
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Traditional, non‐guided bronchoscopy biopsy (NGB group)
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Combined group (EBUS‐GS with VBN)
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: EBUS group
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: EBUS‐GS and combined groups
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Peripheral pulmonary lesions (PPLs) >20 mm in diameter
Number of subjects: 1010
Study: 28169019

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Perceived risk
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Self-efficacy mediation
Number of subjects: 570
Study: 25564782

Group type: EXPERIMENTAL
Intervention: Bronchial suction technique
Number of subjects: 58

Group type: COMPARATOR
Intervention: Disconnection method
Number of subjects: 58
Study: 23425338

Group type: EXPERIMENTAL
Intervention: High-frequency spinal cord stimulation (HFSCS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both HFSCS and sham
Number of subjects: 40
Study: 21526380

Group type: EXPERIMENTAL
Intervention: Anterior decompression and fusion (group A, n = 27)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Posterior laminectomy (group P, n = 29)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Group H (with hyperintensity on MRI, n = 31)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Group L (with hypointensity on MRI, n = 19)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Group N (no signal on MRI, n = 25)
Number of subjects: 56
Study: 18093738

Group type: EXPERIMENTAL
Intervention: Pain training intervention
Number of subjects: 93
Study: 17162166

Group type: EXPERIMENTAL
Intervention: Minimally invasive technique
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 70
Study: 12899105

Group type: EXPERIMENTAL
Intervention: School Functioning Index (SFI) developed for middle schools; specific intervention details not provided.
Number of subjects: 16
Study: 10731459

Group type: EXPERIMENTAL
Intervention: Screened group (n = 416)
Number of subjects: 878

Group type: COMPARATOR
Intervention: Control group (n = 462)
Number of subjects: 878
Study: 9121638

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) using 'Elektronika‐2M' apparatus with a current of 45 microA for 10‐20 min, with courses consisting of 10‐12 treatments.
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard methods of treatment (novocaine blockade, analgesics, etc.)
Number of subjects: 34
Study: 1389525

Group type: COMPARATOR
Intervention: Extended field radiotherapy (RT)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: MOPP chemotherapy
Number of subjects: 89
Study: 4053732

Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 0
Study: 31564217

Group type: EXPERIMENTAL
Intervention: Self-compassion Break
Number of subjects: 129

Group type: COMPARATOR
Intervention: Time Management Control Group
Number of subjects: 129

Group type: COMPARATOR
Intervention: No-Induction Control Group
Number of subjects: 129
Study: 29329493

Group type: EXPERIMENTAL
Intervention: Meloxicam IV 60 mg
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Meloxicam IV 30 mg
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Meloxicam IV 15 mg
Number of subjects: 230

Group type: COMPARATOR
Intervention: Ibuprofen 400 mg
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 27039291

Group type: EXPERIMENTAL
Intervention: Evolocumab (420 mg monthly)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Ezetimibe (10 mg daily)
Number of subjects: 218
Study: 24763888

Group type: EXPERIMENTAL
Intervention: Unilateral spinal anesthesia with hyperbaric bupivacaine (2 ml, 0.5%)
Number of subjects: 50

Group type: COMPARATOR
Intervention: L1 paravertebral block combined with psoas compartment block and sciatic nerve block with bupivacaine hydrochloride (total 35 ml)
Number of subjects: 50
Study: 22838231

Group type: COMPARATOR
Intervention: Vitremer Primer (positive control)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 32% phosphoric acid
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 20% polyacrylic acid
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: self‐etch adhesive (Prompt L Pop)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: etch & rinse adhesive (Prime & Bond NT)
Number of subjects: 6

Group type: COMPARATOR
Intervention: no surface treatment (negative control)
Number of subjects: 6
Study: 20691348

Group type: EXPERIMENTAL
Intervention: Self-ligating (SL) brackets (Damon 3MX)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional ligated (CL) brackets (Victory Series or Mini-Diamond)
Number of subjects: 50
Study: 19025303

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication therapy (10-day course of rabeprazole, amoxicillin, and clarithromycin, followed by 20 mg of rabeprazole for 3 months)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control therapy (20 mg of rabeprazole for 3 months)
Number of subjects: 48
Study: 15636615

Group type: EXPERIMENTAL
Intervention: Steroid stop
Number of subjects: 833

Group type: EXPERIMENTAL
Intervention: MMF stop
Number of subjects: 833

Group type: COMPARATOR
Intervention: Control (triple therapy)
Number of subjects: 833
Study: 14651431

Group type: EXPERIMENTAL
Intervention: MOS-HIV health survey administered at baseline and every 3 months during 1-year follow-up
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: MOS-HIV health survey
Number of subjects: 185
Study: 10965646

Group type: EXPERIMENTAL
Intervention: Family-based behavioral weight-control program plus parent and child problem solving
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Family-based behavioral weight-control program plus child problem solving
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard treatment with no additional problem solving
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Parent + child problem solving
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: All conditions (including child problem solving)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 67
Study: 8980428

Group type: EXPERIMENTAL
Intervention: Infrared optoelectronic system (Perometer)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Water displacement
Number of subjects: 27

Group type: COMPARATOR
Intervention: Disc model method
Number of subjects: 27

Group type: COMPARATOR
Intervention: Frustrum method
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Perometer
Number of subjects: 27

Group type: COMPARATOR
Intervention: Disc method
Number of subjects: 27
Study: 1291328

Group type: EXPERIMENTAL
Intervention: Colgate toothpaste (1000 ppm MFP and 450 ppm NaF)
Number of subjects: 50
Study: 3842878

Group type: EXPERIMENTAL
Intervention: Child life intervention from child life staff
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control A (pediatric hospital)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control B (general hospital)
Number of subjects: 3
Study: 31687764

Group type: EXPERIMENTAL
Intervention: Progression of lesions
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Stability of lesions
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Regression of lesions
Number of subjects: 43
Study: 28510646

Group type: EXPERIMENTAL
Intervention: Switched DAPT (aspirin plus clopidogrel)
Number of subjects: 646

Group type: COMPARATOR
Intervention: Unchanged DAPT (aspirin plus newer P2Y12 blocker)
Number of subjects: 646
Study: 25728888

Group type: EXPERIMENTAL
Intervention: L. reuteri-containing lozenges
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23222534

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM) - 15 mg/kg to a maximum of 1000 mg IV for NDD-CKD; 200 mg IV push for HD-CKD
Number of subjects: 454

Group type: COMPARATOR
Intervention: Standard medical care (SMC) - treatment determined by the investigator, could include oral iron, IV iron or no iron
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Standard medical care (SMC)
Number of subjects: 454
Study: 21570146

Group type: EXPERIMENTAL
Intervention: Self-monitoring with a quantitative urine glucose meter (Group A)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Self-monitoring with a blood glucose meter (Group B)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group without self-monitoring (Group C)
Number of subjects: 108
Study: 19714376

Group type: EXPERIMENTAL
Intervention: SARME with pterygomaxillary disjunction (SARME+PP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: SARME without pterygomaxillary disjunction (SARME-PP)
Number of subjects: 50
Study: 16897144

Group type: EXPERIMENTAL
Intervention: Music stimulation during the procedure
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Music therapeutic coaching
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 83
Study: 15505001

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control
Number of subjects: 95
Study: 11529360

Group type: EXPERIMENTAL
Intervention: Contaminated endometriotic contents during oocyte retrieval
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Non-contaminated endometriotic contents during oocyte retrieval
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 38
Study: 9754167

Group type: EXPERIMENTAL
Intervention: Cryotherapy for ROP (Group A)
Number of subjects: 1465

Group type: COMPARATOR
Intervention: Natural history (Group B)
Number of subjects: 1465
Study: 7918139

Group type: EXPERIMENTAL
Intervention: Simendan 1.0 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Simendan 2.0 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Simendan 5.0 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Simendan 10.0 mg
Number of subjects: 8